Cowen Reiterates Outperform on Histogenics (HSGX) Following FDA Meeting Announcement
Tweet Send to a Friend
Cowen analyst, Joshua Jennings, reiterated an Outperform rating and $3.50 price target on Histogenics Corp. (NASDAQ: HSGX) following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
